

Project	Impact statement:
PAT-U-PAMI	<p>Asthma is the most prevalent chronic respiratory disease worldwide. In children, it is the most common chronic disease, affecting 8-10% worldwide. One of the current effective treatments is to inject omalizumab every 2-3 weeks which is painful, causes bleeding, an increased risk of infection, and needs to be administered by a trained clinician. Our microneedle patch eliminates the need of hypodermic needles and is relatively painless, accurate, and simple for even a parent to use for managing paediatric asthma conditions.</p>